Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo

BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bo, Xia, Meng, Wang, Bin, Thapa, Niresh, Gan, Lijuan, Sun, Chaoyang, Guo, Ensong, Huang, Jia, Lu, Yulan, Cai, Hongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839134/
https://www.ncbi.nlm.nih.gov/pubmed/31703731
http://dx.doi.org/10.1186/s13048-019-0570-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839134/
https://www.ncbi.nlm.nih.gov/pubmed/31703731
http://dx.doi.org/10.1186/s13048-019-0570-9

Ejemplares similares